SuperworthAchieve Life Sciences revenue ACHV
Sales by quarter and over the last twelve months, from 2010.
- Last 12 months, to Mar 31, 2016
- $19.7M
- Latest quarter, Q1 FY16
- $2.9M
- +114% on a year earlier
- Fiscal year 2015
- $18.2M
- −33% on the year before
Achieve Life Sciences' revenue was $19.7M over the twelve months to Mar 31, 2016, up 18% on a year earlier.
In its latest quarter, Q1 FY16, it was $2.9M, up 114% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2015 | $18.2M | −33% |
| FY2014 | $27.1M | −9% |
| FY2013 | $29.9M | +49% |
| FY2012 | $20.1M | +266% |
| FY2011 | $5.5M | n/a |
| FY2010 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY16 | $2.9M | +114% | $19.7M | |
| Q4 FY15 | $6M | +7% | $18.2M | |
| Q3 FY15 | $6.7M | +40% | $17.8M | |
| Q2 FY15 | $4M | −18% | $15.9M | |
| Q1 FY15 | $1.4M | −88% | $16.8M | |
| Q4 FY14 | $5.7M | −34% | $27.1M | |
| Q3 FY14 | $4.8M | −51% | $30.1M | |
| Q2 FY14 | $4.9M | −22% | $35.1M | |
| Q1 FY14 | $11.7M | +131% | $36.5M | |
| Q4 FY13 | $8.6M | −12% | $29.9M | |
| Q3 FY13 | $9.9M | +50% | $31.1M | |
| Q2 FY13 | $6.3M | +161% | $27.8M |
Against its peers
Companies in Medical - Diagnostics & Research nearest Achieve Life Sciences' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| ACHVAchieve Life Sciences | n/m | |
| NRCNRC Health | $140M | −0% a year |
| CDNACareDx | $458.1M | +34% a year |
| VCYTVeracyte | $561.9M | +17% a year |
| ICCCImmucell | $30.7M | +8% a year |
| BLLNBillionToOne | $397.4M | +90% a year |
| LNTHLantheus | $1.6B | +2% a year |
| Peer median | $427.8M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Achieve Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.